A strict gluten-free diet remains the only approved treatment for celiac disease, but a broad pipeline of experimental therapies aims to change that. These range from enzymes that digest gluten in the stomach before it reaches the small intestine, to drugs that seal the gut lining, to immune-targeted treatments designed to retrain the body’s response to gluten entirely. None has yet reached regulatory approval for celiac disease, but several have advanced through mid-stage clinical trials, and the landscape looks more promising than it did even five years ago.
Why the Gluten-Free Diet Is Not Enough
For a condition whose treatment sounds straightforward, the gluten-free diet is surprisingly hard to follow and surprisingly imperfect. Patients with celiac disease report that the burden of maintaining the diet is high compared to other chronic conditions, including those requiring daily medication.1The American journal of gastroenterology. Patient Perception of Treatment Burden is High in Celiac Disease Compared to Other Common Conditions Hidden gluten in processed foods, restaurant meals, and even medications means that accidental exposure is common, and some people remain symptomatic or show ongoing intestinal damage despite doing their best to avoid gluten.
The gap between dietary intention and mucosal healing is especially wide in adults. Children tend to recover quickly on a gluten-free diet, with about 95% achieving complete mucosal recovery within two years. Adults fare much worse: more than half still show villous atrophy after the same two-year window, and up to 30% continue to have symptoms even on a strict diet.2PubMed Central. Age-related differences in celiac disease: Specific characteristics of adult presentation Persistent villous atrophy, whether from poor adherence, slow healing, or gluten hypersensitivity, is linked to a higher risk of complications over time.3PubMed Central. Persistent villous atrophy predicts development of complications and mortality in adult patients with coeliac disease: a multicentre longitudinal cohort study and development of a score to identify high-risk patients All of this creates a strong clinical rationale for adjunct therapies that can pick up where the diet leaves off.
Enzymes That Digest Gluten Before It Can Do Damage
One of the most intuitive therapeutic strategies is to destroy gluten peptides in the stomach before they ever reach the small intestine. Gluten is unusually resistant to human digestive enzymes because of its high proline content, which is why large immunogenic fragments survive the trip through the stomach and duodenum intact. Supplemental enzymes could, in theory, finish the job that our own digestion cannot.
Latiglutenase is an orally administered enzyme mixture that has been tested specifically for this purpose. It is designed to break down gluten fragments produced by inadvertent exposure, not to enable patients to eat pizza freely. In clinical analyses, the focus has been on whether it can improve symptoms and quality of life in patients already on a gluten-free diet who are still exposed to trace amounts of gluten.4PubMed Central. Latiglutenase Treatment for Celiac Disease: Symptom and Quality of Life Improvement for Seropositive Patients on a Gluten-Free Diet The results have been mixed overall. A subgroup of patients who were seropositive, meaning they still had detectable celiac antibodies despite dieting, showed clearer benefit, but the broader trial population did not separate cleanly from placebo. This pattern has made it tricky for enzyme therapies to clear the bar for regulatory approval, though research continues.
Newer work has looked beyond manufactured enzymes to those found in the gut microbiome itself. Researchers have identified prolyl peptidases from specific bacterial species that can degrade the notorious 33-amino-acid gliadin fragment, one of the most immunogenic gluten peptides, under conditions mimicking the human gut. In laboratory models, enzymatic breakdown of these peptides restored expression of tight junction proteins, reduced inflammatory signaling, and improved barrier integrity.5bioRxiv. Gut microbiome-derived prolyl peptidases from Segatella copri and Stenotrophomonas maltophilia degrade immunogenic gliadin peptides and restore intestinal barrier integrity in a Celiac disease model This is still preclinical work, but it suggests that microbial enzymes could eventually be harnessed as a more targeted enzyme supplement.
Sealing the Gut Barrier With Larazotide Acetate
In celiac disease, gluten triggers increased intestinal permeability, sometimes called “leaky gut” in popular language. This happens partly through a molecule called zonulin, which opens the tight junctions between cells lining the intestine. Once those junctions open wider than they should, partially digested gluten fragments pass through the gut wall and reach immune cells that set off the inflammatory cascade.
Larazotide acetate works by blocking zonulin’s action and helping redistribute the proteins that hold tight junctions together, effectively keeping the intestinal barrier sealed.6PubMed Central. Larazotide acetate: a pharmacological peptide approach to tight junction regulation In a randomized trial, larazotide was tested as a way to prevent the activation of celiac disease during a controlled gluten challenge, and it showed the ability to reduce symptoms triggered by gluten exposure.7PubMed Central. A Randomized, Double-Blind Study of Larazotide Acetate to Prevent the Activation of Celiac Disease During Gluten Challenge The drug does not digest or neutralize gluten itself. Instead, it tries to limit the damage gluten can do once swallowed, making it a complementary approach rather than a standalone solution. Larazotide has been one of the furthest-along candidates in the celiac pipeline, though it still awaits definitive phase 3 results.
Blocking the Enzyme That Makes Gluten More Dangerous
Raw gluten peptides are already problematic, but they become far more immunogenic after being modified by an enzyme called tissue transglutaminase, or TG2. This enzyme chemically alters gluten fragments in a way that makes them bind more tightly to the immune system’s presentation molecules, dramatically amplifying the T-cell response. TG2 also crosslinks gluten to itself, creating structures that break immune tolerance not just to gluten but to TG2 as well, which is why celiac disease involves autoantibodies against the body’s own enzyme.8PubMed Central. Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease
ZED1227 is the first TG2 inhibitor to enter clinical testing for celiac disease. In an exploratory proof-of-concept study, it validated TG2 as a viable drug target by demonstrating that blocking this enzyme could reduce gluten-induced mucosal damage. The idea is appealing because it intervenes at a bottleneck in the disease pathway: even if gluten gets through and reaches the intestine, disabling TG2 should prevent it from being supercharged into its most immunogenic form. Whether ZED1227 or a successor TG2 inhibitor will prove effective enough in larger trials remains to be seen, but the mechanism is well supported.
Preventing Gluten From Being Presented to Immune Cells
Celiac disease is one of the few autoimmune conditions with a clearly identified genetic bottleneck. Almost all patients carry specific HLA molecules, with HLA-DQ2 being the most common. These molecules sit on the surface of immune cells and physically present gluten fragments to T cells, triggering the inflammatory response. Without that presentation step, the immune reaction does not happen.
Researchers have explored designing molecules that fit into the HLA-DQ2 binding groove but are not themselves immunogenic, effectively blocking the slot so that gluten fragments cannot be presented. Early work produced cyclic peptide analogues that were stronger inhibitors of DQ2-mediated antigen presentation than reference peptides known to bind DQ2 with high affinity.9PubMed Central. CYCLIC AND DIMERIC GLUTEN PEPTIDE ANALOGUES INHIBITING DQ2-MEDIATED ANTIGEN PRESENTATION IN CELIAC DISEASE The logic is that if gluten peptide binding to HLA-DQ molecules is a prerequisite for the inflammatory T-cell response, then blockers preventing that binding could serve as an alternative to dietary restriction.10PubMed. Design, synthesis and evaluation of high-affinity binders for the celiac disease associated HLA-DQ2 molecule
This approach is still largely in preclinical stages. The main challenges are selectivity and delivery: these blockers need to occupy HLA-DQ2 on immune cells in the gut mucosa without disrupting antigen presentation for everything else the immune system needs to respond to. It is a promising concept that has not yet translated into a candidate ready for large-scale human testing.
Retraining the Immune System
The most ambitious therapies aim not just to limit damage from gluten exposure but to restore the immune system’s tolerance to gluten entirely. Two distinct approaches have been tested in clinical trials.
Nanoparticle-Based Tolerance (TAK-101)
TAK-101 uses biodegradable nanoparticles loaded with gliadin, the immunogenic protein in gluten, to try to reprogram the immune response. In a randomized, double-blind, placebo-controlled study, intravenous TAK-101 reduced the gluten-challenge-induced T-cell response by roughly 90% compared to baseline, and this effect was antigen-specific, meaning the drug damped down the response to gluten without broadly suppressing immunity.11PubMed Central. TAK-101 Nanoparticles Induce Gluten-Specific Tolerance in Celiac Disease: A Randomized, Double-Blind, Placebo-Controlled Study That antigen-specificity is the key selling point. Unlike broad immunosuppressants, a tolerance-inducing therapy could let people eat gluten again without leaving them vulnerable to infections or other immune threats. Further trials are needed to confirm whether this early immune signal translates into clinical protection and mucosal healing.
Peptide Immunotherapy (Nexvax2)
Nexvax2 took a different route toward the same goal. It used three immunodominant gluten peptides, the specific fragments that gluten-reactive T cells recognize most strongly, injected in gradually escalating doses to try to desensitize the immune system. Phase 1 testing showed that a slow dose-escalation protocol could avoid the acute gastrointestinal symptoms and cytokine release that had limited earlier dosing, allowing maintenance doses up to 900 micrograms in some patients without immune activation.12PubMed Central. Epitope-Specific Immunotherapy Targeting CD4-Positive T Cells in Celiac Disease: Safety, Pharmacokinetics, and Effects on Intestinal Histology and Plasma Cytokines with Escalating Dose Regimens of Nexvax2 in a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study In a dose-finding study, higher doses produced higher rates of negative interferon-gamma release assays, suggesting successful immune modulation.13The Lancet Gastroenterology & Hepatology. Safety, pharmacodynamics, and potential therapeutic effect of Nexvax2 in patients with coeliac disease initialise
However, the subsequent phase 2 trial was terminated early. An interim analysis found that Nexvax2 did not protect against symptoms during a gluten challenge compared to placebo.14PubMed. Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to gluten (RESET CeD): an interim analysis of a terminated randomised, double-blind, placebo-controlled phase 2 study The failure of Nexvax2 does not mean immune tolerance is impossible in celiac disease, but it does illustrate how hard it is to move from encouraging immune markers to actual clinical improvement. The gluten-reactive T-cell response in celiac disease is driven by multiple epitopes, and a three-peptide vaccine may simply not cover enough of the immune response to make a difference when patients face whole gluten from food.
Targeting IL-15 in Celiac Inflammation
Interleukin-15 is a cytokine that plays a central role in celiac disease by driving the activation, survival, and cytotoxic behavior of immune cells in the gut lining. It promotes a type of runaway lymphocyte activity that contributes directly to tissue damage and, in extreme cases, to the development of lymphoma.15Gut. Epithelium derived interleukin 15 regulates intraepithelial lymphocyte Th1 cytokine production, cytotoxicity, and survival in coeliac disease Blocking IL-15 could suppress this uncontrolled immune activation and restore normal lymphocyte turnover.
AMG714, a humanized monoclonal antibody against IL-15, has shown the ability in laboratory experiments on patient tissue to inhibit the signaling pathways that keep these immune cells alive and proliferating. In mouse models that overexpress IL-15, treatment with this antibody restored normal cell death in gut lymphocytes and reduced their accumulation.16PubMed Central. IL-15: a central regulator of celiac disease immunopathology Clinical trials in humans have explored whether blocking IL-15 can reduce mucosal damage, and this approach is especially relevant for patients with refractory celiac disease, where the diet alone does not control the abnormal lymphocyte population.
Treatments for Refractory Celiac Disease
A small percentage of celiac patients develop refractory disease, meaning their symptoms and intestinal damage persist or return despite strict gluten avoidance. Refractory celiac disease is divided into two types: type I, which generally responds to immunosuppressive therapy, and type II, which involves a clonal expansion of abnormal lymphocytes in the gut and carries a high risk of progressing to lymphoma. Type II is the more dangerous form and the harder one to treat.
For type II refractory celiac disease, several drugs have been tried. Cladribine, a chemotherapy agent, produced clinical response in about 81% of patients at two years, though complete histological recovery occurred in fewer than half. Patients who responded had markedly better survival rates: about 83% at five years compared to just 22% in those who did not respond.17World Journal of Gastroenterology. Evaluation of Cladribine treatment in refractory celiac disease type II Other agents that have been tried include azathioprine, cyclosporine, infliximab, and alemtuzumab, though evidence for most of these comes from case reports rather than controlled trials, and publication bias likely overstates their effectiveness.18PubMed Central. Classification and Management of Refractory Celiac Disease
A more recent and potentially significant development is the use of tofacitinib, a JAK inhibitor already approved for rheumatoid arthritis and ulcerative colitis. In an open-label study, tofacitinib produced prompt clinical remission and histological improvement in type II refractory patients, with enduring remission during extended follow-up and no unexpected safety concerns.19Clinical Gastroenterology and Hepatology. Enduring Clinical Remission in Refractory Celiac Disease Type II With Tofacitinib: An Open-Label Clinical Study If confirmed in larger studies, tofacitinib could represent the first targeted therapy for a condition that has historically been treated with blunt immunosuppression and chemotherapy.
Microbiome-Based Approaches
The gut microbiome in celiac disease differs from that of healthy individuals, and this has led to interest in whether probiotics or other microbiome-targeted interventions could play a therapeutic role. Some probiotic strains can break down immunogenic gluten peptides, reducing their ability to trigger an immune response. They have also been shown to influence immune regulation, promoting the development of anti-inflammatory regulatory T cells.20PubMed Central. Gut Microbiota in Celiac Disease: Is There Any Role for Probiotics?
Specific probiotic formulations have been tested for their ability to hydrolyze gliadin. One well-studied cocktail of eight bacterial strains was found to be highly effective at breaking down gliadin polypeptides during prolonged fermentation compared to other commercial probiotic products, with particular strength in the enzymes that digest proline-rich peptides, which are the segments of gluten most resistant to normal digestion.21PubMed Central. Intestinal Microbiota and Probiotics in Celiac Disease Whether taking these probiotics as a supplement meaningfully reduces gluten-related harm in real-world eating situations is still unclear. The fermentation conditions in a lab are very different from the transit time and pH environment of a living gut. Probiotics remain a plausible adjunct rather than a proven therapy for celiac disease.
Better Ways to Monitor Gluten Exposure
One of the underappreciated challenges in developing celiac disease therapies is measuring whether they actually work. Traditional monitoring relies on blood antibodies and intestinal biopsies, both of which have significant limitations. Antibodies take weeks to change and can be unreliable in patients already on a gluten-free diet. Biopsies are invasive, expensive, and subject to sampling error. Clinical trials need more responsive and objective measures of whether a drug is reducing the impact of gluten exposure.
Gluten immunogenic peptides, or GIP, offer a more direct approach. These are fragments of gluten that survive digestion and can be detected in stool and urine, providing a non-invasive, specific marker of actual gluten intake rather than an indirect immune consequence of it.22PubMed Central. Determination of gluten immunogenic peptides for the management of the treatment adherence of celiac disease: A systematic review Point-of-care kits are now being evaluated that could allow GIP testing without a specialized laboratory.23PubMed Central. Comparing urine and stool gluten immunogenic peptides for detecting compliance to gluten-free diets For patients, this could mean real-time feedback on whether accidental gluten exposure has occurred. For clinical trials, it could help researchers distinguish between drug failure and simple non-compliance.
Regulatory bodies face their own challenges in approving celiac therapies. Unlike many diseases where a single primary endpoint is standard, celiac trials likely need a combination of patient-reported symptom improvement and a more objective biomarker such as villus-height-to-crypt-depth ratio from biopsies.24PubMed Central. Development of drugs for celiac disease: review of endpoints for Phase 2 and 3 trials The high placebo response rates in celiac trials, partly because patients are already on a gluten-free diet and symptoms fluctuate naturally, make trial design particularly tricky. This is one reason several promising-looking candidates have stumbled in late-stage trials.
Engineering Wheat That Does Not Trigger Celiac Disease
Rather than treating the immune response to gluten, another approach asks whether the gluten itself could be made less dangerous at the source. Wheat contains several families of gliadin proteins, and the gamma and omega gliadins are among the most immunogenic. Using CRISPR gene-editing technology, researchers have introduced targeted mutations into the genes encoding these gliadin fractions, producing wheat lines deficient in one or both families simultaneously.25Journal of Experimental Botany. CRISPR/Cas9-mediated multiplex gene editing of gamma and omega gliadins: paving the way for gliadin-free wheat
Wheat presents an unusual genetic challenge for this kind of work because it has a large, hexaploid genome with dozens of copies of gliadin genes scattered across multiple chromosomes. Knocking out all the immunogenic gliadins while maintaining the baking properties that make wheat useful as a food crop is a genuine technical hurdle. The edited lines produced so far represent important proof-of-concept work, but commercial gliadin-free wheat is still years away at best. And even if such wheat reaches the market, regulatory acceptance, consumer trust, and the question of whether eliminating some gliadins truly eliminates the celiac trigger will all need to be resolved.
Sex Differences in Celiac Disease and Their Therapeutic Implications
Celiac disease affects more women than men, which is typical of autoimmune conditions, but the downstream effects of the disease may differ between sexes in ways that are only beginning to be understood. In a mouse model engineered to carry the human celiac-associated HLA genes, males and females developed comparable intestinal damage when exposed to gluten. However, only males went on to develop impaired blood vessel function, vascular and heart inflammation, and broader metabolic disturbances. Female mice were largely protected, and when researchers pharmacologically inhibited estrogen production, vascular relaxation worsened, pointing to sex hormones as a protective factor.26Scientific Reports. Sex-related differences in cardiovascular inflammation and metabolomics in a humanized transgenic mouse model of celiac disease
This finding is still from an animal model, so direct translation to human patients requires caution. But it raises the possibility that celiac disease has extra-intestinal consequences that differ by sex, and that future therapies might need to account for cardiovascular risk in male patients specifically. It also reinforces a broader theme in celiac research: the disease is not just about the gut. Systemic inflammation, nutrient malabsorption, bone loss, neurological symptoms, and now possibly cardiovascular complications all point to a condition whose full impact extends well beyond the intestinal lining. Therapies that address only the mucosal damage may leave other aspects of the disease unmanaged.